Sensitivity and specificity of clinical diagnosis of Graves’ disease and non-Graves’ disorders compared to serum TSH receptor antibodies

Mohammed Qader Meena

doi:10.15218/zjms.2022.002

Authors

Mohammed Qader Meena Department of Medicine, College of Medicine, Hawler Medical University, Erbil, Iraq.

DOI:

https://doi.org/10.15218/zjms.2022.002

Keywords:

Graves’ disease, oral hygiene, dmfs, Toxic multinodular goiter, Thyroiditis

Abstract

Background and objective: Sensitivity and specificity of clinical diagnosis of different hyperthyroid conditions were studied and compared with serum thyrotropin receptor antibodies test, as a standard test for diagnosing Graves' disease. This study aimed to assess the degree of sensitivity and specificity of clinical diagnosis of hyperthyroid conditions compared to the thyrotropin receptor antibodies test, which was selected as a standard test for diagnosis of Graves’ disease in the study.

Methods: We studied patients presenting to endocrine outpatient clinics and other outpatient settings in Erbil city, presenting with clinical features of thyrotoxicosis. Serum or plasma thyroid-stimulating hormone, free T4, and thyrotropin receptor antibodies measurements were done for all the patients. Thyroid peroxidase antibodies and thyroid ultrasonography were done for most patients. Radioactive thyroid uptake was available for a limited number of patients. Sensitivity, specificity, positive predictive value, negative predictive value, positive likelihood ratio, negative likelihood ratio, and accuracy index of clinical diagnosis of the thyrotoxicosis cases were calculated.

Results: A total of 150 patients were included in our study, female 102, males 48, mean age 38 (range 16-78) years, pretest diagnosis of (Graves’ disease N=58, and non-Graves’ disease N=92 and posttest diagnosis of (Graves’ disease n= 59 vs. non-Graves’ disease=91). Sensitivity of 74.6%, specificity (84.60%), positive predictive value (75.9%), negative predictive value (83.7%), positive likelihood ratio (4.847), negative likelihood ratio (0.30), and accuracy index (80.7%) of the clinical diagnosis were estimated.

Conclusion: The study showed that clinical diagnosis of Graves' disease and non-Graves’ disease disorders, using thorough clinical examination and primary essential investigations, has high sensitivity and specificity index. However, the serum thyrotropin receptor antibodies test remains the standard method in the differential diagnosis of Graves' disease. Other studies are needed to study ultrasound and scintigraphy compared to the thyrotropin receptor antibodies test.

Metrics

Metrics Loading ...

References

Kahaly GJ, Bartalena L, Hegedüs L. The American Thyroid Association/American Association of Clinical Endocrinologists guidelines for hyperthyroidism and other causes of thyrotoxicosis: A European perspective. Thyroid. 2011;21(6):585–91. https://doi.org/10.1089/thy.2011.2106.ed3.

Anthony H, Wilmar MW. Hyperthyroid Disorders. In:Shlomo M, Richard JA, Allison BG, editors. Williams Textbook of Endocrinology.14th ed. Philadelphia: Elsevier; 2020. P. 452–3.

Matthews DC, Syed AA. The role of TSH receptor antibodies in the management of Graves' disease. Eur J Intern Med. 2011;22(3):213–6. https://doi.org/10.1016/j.ejim.2011.02.006.

Vasileiou M, Gilbert J, Fishburn S, Boelaert K; Guideline Committee. Thyroid disease assessment and management: summary of NICE guidance. BMJ. 2020;368:m41. https://doi.org/10.1136/bmj.m41.

Bell L, Hunter AL, Kyriacou A, Mukherjee A, Syed AA. Clinical diagnosis of Graves’ or non-Graves’ hyperthyroidism compared to TSH receptor antibody test. Endocrine Connections. 2018;7(4):504–10. https://doi.org/10.1530/EC-18-0082.

Bahn Chair RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011;21(6):593–646. https://doi.org/10.1089/thy.2010.0417.

Tozzoli R, Bagnasco M, Giavarina D, Bizzaro N. TSH receptor autoantibody immunoassay in patients with Graves’ disease: improvement of diagnostic accuracy over different generations of methods. Systematic review and meta- analysis. Autoimmun Rev. 2012;12(2):107–13. https://doi.org/10.1016/j.autrev.2012.07.003.

Smith TJ, Hegedüs L. Graves' Disease. N Engl J Med. 2016;375(16):1552–65. https://doi.org/10.1056/NEJMra1510030.

Bartalena L. Diagnosis and management of Graves’ disease: a global overview. Nat Rev Endocrinol. 2013;9(12):724–34. https://doi.org/10.1038/nrendo.2013.193.

Bartalena L, Burch HB, Burman KD, Kahaly GJ. A 2013 European survey of clinical practice patterns in the management of Graves’ disease. Clin Endocrinol. 2016;84(1):115–20. https://doi.org/10.1111/cen.12688.

Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SH. European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism. Eur Thyroid J. 2018;7(4):167–86. https://doi.org/10.1159/000490384.

Scappaticcio L, Trimboli P, Keller F, Imperiali M, Piccardo A, Giovanella L. Diagnostic testing for Graves’ or non-Graves’ hyperthyroidism: A comparison of two thyrotropin receptor antibody immunoassays with thyroid scintigraphy and ultrasonography. Clin Endocrinol (Oxf). 2020;92(2):169–78. https://doi.org/10.1111/cen.14130.

Meena MQ. Diagnosing Graves’ Disease and non-Graves hyperthyroidism using TSH receptor antibody test versus non-TSH receptor antibody test methods of diagnosis. Open Journal of Endocrine and Metabolic Diseases. 2020;10(2):7–17. https://doi.org/10.4236/ojemd.2020.102002.

Diana T, Wüster C, Kanitz M, Kahaly GJ. Highly variable sensitivity of five binding and two bio-assays for TSH-receptor antibodies. Journal of Endocrinological Investigation. 2016;39(10):1159–65. https://doi.org/10.1007/s40618-016-0478-9.

Barbesino G, Tomer Y. Clinical utility of TSH receptor antibodies. J Clin Endocrinol Metab. 2013;98(6):2247–55. https://doi.org/10.1210/jc.2012-4309.

Kamath C, Adlan MA, Premawardhana LD. The role of thyrotrophin receptor antibody assays in graves' disease. J Thyroid Res. 2012;2012:525936. https://doi.org/10.1155/2012/525936.

Beastall GH, Beckett GJ, Franklyn JA, Fraser WD, Hickey J, John R, et al. British Thyroid Association. U K Guidelines for the use of thyroid function tests. (Accessed October 2, 2020, available at http://www.british-thyroid-association.org).

Syme NR, Toft AD, Stoddart M, Beckett GJ. Clinical performance of the Roche Cobase411 automated assay system for thyrotropin-receptor antibodies for the diagnosis of Graves' disease. Ann Clin Biochem. 2011;48(5):471–3. https://doi.org/10.1258/acb.2011.011013.

Rugge JB, Bougatsos C, Chou R. Screening and treatment of thyroid dysfunction: an evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2015;162(1):35–45. https://doi.org/10.7326/M14-1456.